Tasigna — CareFirst (Caremark)

Initial criteria

• Requested for treatment of PVNS or TGCT as a single agent

Reauthorization criteria

• No evidence of unacceptable toxicity or disease progression while on the current regimen

Approval duration

Initial and continuation 12 months